This is a very interesting video presentation consisting of lung cancer experts and EGFR Resisters co-founder Jill Feldman discussing the treatment options after osimertinib (Tagrisso) faillure. It covers:
- Importance of liquid and tissue biopsies to check for new mutations
- chemo is standard of care
- amivantamab +lazertinib
- clinical trials
- When considering next treatment: Were drug approvals based on PFS or OS? How will quality of life change?
- Keeping certain treatments as options in your back pocket for future lines of therapy, rather than aggressively employing multiple combinations in one line of therapy.